Differentiation of malignant tumours from granulomas by using dynamic [18F]-fluoro-L-α-methyltyrosine positron emission tomography

BackgroundPrevious clinical studies have revealed the potential of [18F]-fluoro-L-α-methyltyrosine (18F-FAMT) for the differential diagnosis of malignant tumours from sarcoidosis. However, one concern regarding the differential diagnosis with 18F-FAMT is the possibility of false negatives given the small absolute uptake of 18F-FAMT that has been observed in some malignant tumours. The aim of this study was to evaluate a usefulness of dynamic 18F-FAMT positron emission tomography (PET) for differentiating malignant tumours from granulomas.MethodsRats bearing both granulomas (Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced) and tumours (C6 glioma cell-induced) underwent dynamic 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) PET and 18F-FAMT PET for 120 min on consecutive days. Time-activity curves, static images, mean standardized uptake values (SUVs) and the SUV ratios (SUVRs; calculated by dividing SUV at each time point by that of 2 min after injection) were assessed.ResultsIn tumours, 18F-FAMT showed a shoulder peak immediately after the initial distribution followed by gradual clearance compared with granulomas. Although the mean SUV in the tumours (1.00 ± 0.10) was significantly higher than that in the granulomas (0.88 ± 0.12), a large overlap was observed. In contrast, the SUVR was markedly higher in tumours than in granulomas (50 min/2 min, 0.72 ± 0.06 and 0.56 ± 0.05, respectively) with no overlap. The dynamic patterns, SUVR, and mean SUV of 18F-FDG in the granulomas were comparable to those in the tumours.ConclusionsDynamic 18F-FAMT and SUVR analysis might compensate for the current limitations and help in improving the diagnostic accuracy of 18F-FAMT.

[1]  N. Tamaki,et al.  Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  S. Alyafei,et al.  Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  H. Kimura,et al.  Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  S. Larson Cancer or inflammation? A Holy Grail for nuclear medicine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  R. Iwata,et al.  Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  K. Ohata,et al.  Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? , 2003, Journal of neurosurgery.

[8]  N. Tamaki,et al.  Usefulness of 11C-Methionine for Differentiating Tumors from Granulomas in Experimental Rat Models: A Comparison with 18F-FDG and 18F-FLT , 2007, Journal of Nuclear Medicine.

[9]  N. Tamaki,et al.  Usefulness of 11 C-Methionine for Differentiating Tumors from Granulomas in Experimental Rat Models : A Comparison with 18 F-FDG and 18 F-FLT , 2017 .

[10]  K. Langen,et al.  Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Keigo Endo,et al.  Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. , 2007, Chest.

[12]  S. Bröer,et al.  Amino acid transport across mammalian intestinal and renal epithelia. , 2008, Physiological reviews.

[13]  David J. Yang,et al.  Synthesis of isomers of 18F‐labelled amino acid radiopharmaceutical: Position 2− and 3‐L‐18F-α‐methyltyrosine using a separation and purification system , 1997, Nuclear medicine communications.

[14]  Takashi Nakajima,et al.  Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study , 2007, Clinical Cancer Research.

[15]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Y. Kanai,et al.  Expression of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models , 2001, Journal of surgical oncology.

[17]  H. Hanaoka,et al.  PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients , 2006, International Journal of Clinical Oncology.

[18]  Sang Moo Lim,et al.  Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. , 2009, Nuclear medicine and biology.

[19]  N. Tamaki,et al.  Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  M. Schwaiger,et al.  Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  J Aoki,et al.  Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. , 2001, Radiology.

[22]  大亀 浩久 Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models , 2003 .

[23]  S. Morita,et al.  18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry , 2010, Annals of nuclear medicine.

[24]  A. Krüger,et al.  O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Keigo Endo,et al.  Transport of 3-Fluoro-l-α-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET , 2012, The Journal of Nuclear Medicine.

[26]  Takashi Nakajima,et al.  Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: A clinicopathological study , 2009, International journal of cancer.